Luis E Rohde

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5533731/publications.pdf

Version: 2024-02-01

394421 243625 2,040 57 19 44 citations h-index g-index papers 60 60 60 3654 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Heart failure: preventing disease and death worldwide. ESC Heart Failure, 2014, 1, 4-25.	3.1	921
2	IRON-HF study: A randomized trial to assess the effects of iron in heart failure patients with anemia. International Journal of Cardiology, 2013, 168, 3439-3442.	1.7	192
3	Cost-effectiveness of heart failure therapies. Nature Reviews Cardiology, 2013, 10, 338-354.	13.7	66
4	Serum levels and polymorphisms of matrix metalloproteinases (MMPs) in carotid artery atherosclerosis: higher MMP-9 levels are associated with plaque vulnerability. Biomarkers, 2014, 19, 49-55.	1.9	61
5	Reliability and prognostic value of traditional signs and symptoms in outpatients with congestive heart failure. Canadian Journal of Cardiology, 2004, 20, 697-702.	1.7	57
6	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and HeartÂFailure Cause. JACC: Heart Failure, 2020, 8, 844-855.	4.1	56
7	An Analysis of the Global Expression of MicroRNAs in an Experimental Model of Physiological Left Ventricular Hypertrophy. PLoS ONE, 2014, 9, e93271.	2.5	53
8	Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial. European Heart Journal, 2019, 40, 3605-3612.	2.2	46
9	Transcoronary gradient of plasma microRNA 423-5p in heart failure: evidence of altered myocardial expression. Biomarkers, 2014, 19, 135-141.	1.9	43
10	A Hemodynamically Oriented Echocardiography-Based Strategy in the Treatment of Congestive Heart Failure. Journal of Cardiac Failure, 2007, 13, 618-625.	1.7	42
11	Posicionamento sobre Diagnóstico e Tratamento da Amiloidose CardÃaca – 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 561-598.	0.8	35
12	Effect of caffeine on ventricular arrhythmia: a systematic review and meta-analysis of experimental and clinical studies. Europace, 2016, 18, 257-266.	1.7	33
13	Short-term Effects of High-Dose Caffeine on Cardiac Arrhythmias in Patients With Heart Failure. JAMA Internal Medicine, 2016, 176, 1752.	5.1	28
14	Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: The perspective of a middle-income country's public health system. International Journal of Cardiology, 2013, 163, 309-315.	1.7	27
15	Aggressive fluid and sodium restriction in decompensated heart failure with preserved ejection fraction: Results from a randomized clinical trial. Nutrition, 2018, 54, 111-117.	2.4	24
16	Plasma levels of microRNA-21, -126 and -423-5p alter during clinical improvement and are associated with the prognosis of acute heart failure. Molecular Medicine Reports, 2018, 17, 4736-4746.	2.4	24
17	Dietary vitamin K intake and anticoagulation in elderly patients. Current Opinion in Internal Medicine, 2007, 6, 120-124.	1.5	23
18	Association between serum lactate levels and mortality in patients with cardiogenic shock receiving mechanical circulatory support: a multicenter retrospective cohort study. BMC Cardiovascular Disorders, 2020, 20, 496.	1.7	22

#	Article	IF	Citations
19	Nurses' performance in classifying heart failure patients based on physical exam: comparison with cardiologist's physical exam and levels of Nâ€terminal proâ€Bâ€type natriuretic peptide. Journal of Clinical Nursing, 2010, 19, 3381-3389.	3.0	21
20	Circulating microRNAs in obese and lean heart failure patients: A case–control study with computational target prediction analysis. Gene, 2015, 574, 1-10.	2.2	21
21	Longâ€ŧerm Costâ€Effectiveness of Diagnostic Tests for Assessing Stable Chest Pain: Modeled Analysis of Anatomical and Functional Strategies. Clinical Cardiology, 2016, 39, 249-256.	1.8	20
22	Effect of sacubitril/valsartan on investigatorâ€reported ventricular arrhythmias in <scp>PARADIGMâ€HF</scp> . European Journal of Heart Failure, 2022, 24, 551-561.	7.1	20
23	Matrix Metalloproteinase-2 Polymorphisms in Chronic Heart Failure: Relationship with Susceptibility and Long-Term Survival. PLoS ONE, 2016, 11, e0161666.	2.5	13
24	GDF-15 como Biomarcador em Doenças Cardiovasculares. Arquivos Brasileiros De Cardiologia, 2021, 116, 494-500.	0.8	13
25	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. Circulation: Heart Failure, 2021, 14, e008052.	3.9	13
26	Atualização de Tópicos Emergentes da Diretriz Brasileira de Insuficiência CardÃaca – 2021. Arquivos Brasileiros De Cardiologia, 2021, 116, 1174-1212.	0.8	13
27	Superoxide Dismutase Activity in Adriamycin-Induced Cardiotoxicity in Humans: A Potential Novel Tool for Risk Stratification. Journal of Cardiac Failure, 2005, 11, 220-226.	1.7	12
28	Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction. International Journal of Cardiovascular Imaging, 2007, 23, 185-191.	1.5	12
29	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a <scp>PARADIGMâ€HF</scp> analysis. European Journal of Heart Failure, 2021, 23, 1346-1356.	7.1	11
30	Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients. Journal of Thrombosis and Thrombolysis, 2014, 37, 338-344.	2.1	8
31	Predictors of serious arrhythmic events in patients with nonischemic heart failure. Journal of Interventional Cardiac Electrophysiology, 2017, 48, 131-139.	1.3	8
32	Rational and design of a randomized, double-blind, multicenter trial to evaluate the safety and tolerability of furosemide withdrawal in stable chronic outpatients with heart failure: The ReBIC-1 trial. American Heart Journal, 2017, 194, 125-131.	2.7	8
33	Revisiting heart failure assessment based on objective measures in NYHA functional classes I and II. Heart, 2021, 107, 1487-1492.	2.9	8
34	Implications of the Hemodynamic Optimization Approach Guided by Right Heart Catheterization in Patients with Severe Heart Failure. Arquivos Brasileiros De Cardiologia, 2002, 78, 261-266.	0.8	7
35	QRS Widening Rates and Genetic Polymorphisms of Matrix Metalloproteinases in a Cohort of Patients With Chronic Heart Failure. Canadian Journal of Cardiology, 2014, 30, 345-351.	1.7	7
36	Relationship of polymorphisms in the tissue inhibitor of metalloproteinase (TIMP)-1 and -2 genes with chronic heart failure. Scientific Reports, 2018, 8, 9446.	3.3	7

#	Article	IF	CITATIONS
37	Cost-Effectiveness of a Home Visit Program for Patients with Heart Failure in Brazil: Evidence from a Randomized Clinical Trial. Value in Health Regional Issues, 2018, 17, 81-87.	1.2	7
38	Preditores de Mortalidade Total e Eventos ArrÃtmicos Graves em Pacientes com Insuficiência CardÃaca Não Isquêmica: O Papel da Galectina-3. Arquivos Brasileiros De Cardiologia, 2021, 117, 531-541.	0.8	6
39	Alcohol and the heart: the good, the bad and the worse in heart failure. Heart, 2018, 104, 1641-1642.	2.9	5
40	Characterization of advanced glycation end products and their receptor (RAGE) in an animal model of myocardial infarction. PLoS ONE, 2019, 14, e0209964.	2.5	5
41	Heart failure: preventing disease and death worldwide. ESC Heart Failure, 2014, 1, n/a-n/a.	3.1	5
42	Growth/differentiation factor-15 (GDF-15) as a predictor of serious arrhythmic events in patients with nonischemic dilated cardiomyopathy. Journal of Electrocardiology, 2021, 70, 19-23.	0.9	5
43	N-acetylcysteine Plus Deferoxamine Improves Cardiac Function in Wistar Rats After Non-reperfused Acute Myocardial Infarction. Journal of Cardiovascular Translational Research, 2015, 8, 328-337.	2.4	4
44	Sudden cardiac death markers in non-ischemic cardiomyopathy. Journal of Electrocardiology, 2016, 49, 446-451.	0.9	4
45	COVID-19 in Brazil: the headlines should be about science. Lancet, The, 2020, 396, 1803.	13.7	4
46	Identification of environmental and genetic factors that influence warfarin time in therapeutic range. Genetics and Molecular Biology, 2020, 43, e20190025.	1.3	3
47	The tip of the iceberg in the sub-Saharan Africa: unraveling the real world in the diagnosis and treatment of heart failure. Heart, 2017, 103, 1842-1843.	2.9	1
48	Why do poor patients have poor outcomes? Shedding light on the neglected facet of poverty and heart failure. Heart, 2021, 107, 178-179.	2.9	1
49	Tumorlike Cardiac Fungal Mycetoma Caused by <i>Scedosporium apiospermum</i> Presenting as Symptomatic Ventricular Tachycardia. Circulation, 2014, 129, e488-9.	1.6	0
50	Vaccinations in Heart Failure. JACC: Heart Failure, 2018, 6, 856-858.	4.1	0
51	Effects of a diuretic adjustment algorithm protocol on heart failure admissions: A randomized clinical trial. Journal of Telemedicine and Telecare, 2021, 27, 288-297.	2.7	0
52	The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant. Arquivos Brasileiros De Cardiologia, 2019, 112, 791-792.	0.8	0
53	Doses altas versus baixas de inibidores da eca em insuficiência cardÃaca. , 0, , .		0
54	Tópicos Emergentes em Insuficiência CardÃaca: Perspectivas Futuras. Arquivos Brasileiros De Cardiologia, 2020, 115, 1197-1200.	0.8	0

Luis E Rohde

#	Article	IF	CITATIONS
55	Algorithms for Cardiac Amyloidosis Diagnosis: How to apply them in practice?. , 2021, 1, 139-143.		0
56	Reduction of dietary sodium for heart failure: a step forward. Lancet, The, 2022, 399, 1361-1363.	13.7	0
57	Is There Room for Sacubitril-Valsartan in the Treatment of Advanced Heart Failure?. , 2022, 2, 192-194.		O